<DOC>
	<DOCNO>NCT00219765</DOCNO>
	<brief_summary>The aim phase I/II trial determine dose daunorubicine associate cytarabine Imatinib induction therapy patient chronic myelogenous leukemia myeloid acute phase .</brief_summary>
	<brief_title>Safety Efficacy Imatinib Combination With High Dose Chemotherapy Acute Phase Chronic Myelogenous Patients</brief_title>
	<detailed_description>Study design Imatinib : starting day –3 : 600mg/day ; continuous administration In combination cytarabine : continuous iv/24h : 100mg/m² ; 7 day daunorubicine : 4 level level 1 : 0 level 2 : 15mg/m² ; 3 day level 3 : 30mg/m² ; 3 day level 4 : 45mg/m² ; 3 day</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>CML Ph+ ( assess cytogenetic FISH ) Acute phase ≥ 20 % bone marrow blast ( M0 M6 , exclude M3 ) Age ≥ 18 year inclusion PS grade 0 2 ( ECOG ) Adequate organ function , define follow : total bilirubin &lt; 1.5x uln , sgpt &lt; 3x uln , creatinine &lt; 1.5x uln . Informed consent sign active malignancy CML nonmelanoma cancer skin current treatment another investigational agent patient grade 3/4 cardiac disease serious concurrent medical condition . patient pregnant nursing . All patient childbearing potential must practice effective method contraception study . patient mental illness condition preclude ability give inform consent comply study requirement patient performans status 34</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>CML</keyword>
	<keyword>Acute Phase</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Daunorubicine</keyword>
</DOC>